News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nortal Investments Acquires Additional Shares in PledPharma

January 9, 2013

PledPharma AB
Company Announcement

Nortal Investments Acquires Additional Shares in PledPharma

Stockholm, 2013-01-09 15:37 CET (GLOBE NEWSWIRE) -- Staffan Persson, Nortal
Investments AB, PledPharma’s largest shareholder, has acquired an additional
100 000 shares in PledPharma. This means that Staffan Persson’s family and
company owns a total of 5, 068,052 shares. After the acquisition, Nortal
Investments’ stake in PledPharma is estimated to 25% of the votes and capital. 

“PledPharma has just begun a key phase llb study where the company carries out
a clinical trial in humans on its patented substance PledOx. If PledPharma
succeeds with this study it can lead to significant opportunities for the
company, as PledOx can reduce serious side effects of chemotherapy when
treating cancer. Obviously one should be humble, given the development phase
the company is in. But if PledPharma succeeds then shareholders will be highly
rewarded”, says Staffan Persson, Nortal Investment. 

“We are glad that Nortal Investment proceeds to invest in PledPharma. It is
reassuring that the largest shareholder have a continued confidence in our
business”, says PledPharma’s CEO Jacques Näsström. 

For further information please contact

Staffan Persson, Nortal Investments,

Jacques Näsström, CEO PledPharma, +46 737 13 09 79, 

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx™, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For further information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10